CLINICAL TRIALS PROFILE FOR OSMITROL 15% IN WATER IN PLASTIC CONTAINER

All Clinical Trials for OSMITROL 15% IN WATER IN PLASTIC CONTAINER

Trial ID	Title	Status	Sponsor	Phase	Start Date	Summary
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	Oregon Health and Science University	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00293475 ↗	Methotrexate, Mannitol, Rituximab, and Carboplatin in Treating Patients With Newly Diagnosed Primary Central Nervous System Lymphoma	Active, not recruiting	OHSU Knight Cancer Institute	Phase 1/Phase 2	2005-10-14	This phase I/II trial studies the side effects of methotrexate, mannitol, rituximab, and carboplatin and to see how well they work in treating patients with primary central nervous system lymphoma. Drugs used in chemotherapy, such as methotrexate and carboplatin, work in different ways to stop the growth of cancer cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Monoclonal antibodies, such as rituximab, may block cancer growth in different ways by targeting certain cells. Giving methotrexate, mannitol, rituximab, and carboplatin together may be an effective treatment for primary central nervous system lymphoma.
NCT00303849 ↗	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Completed	National Cancer Institute (NCI)	Phase 1/Phase 2	2005-09-15	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.
NCT00303849 ↗	Carboplatin, Melphalan, Etoposide Phosphate, Mannitol, and Sodium Thiosulfate in Treating Patients With Previously Treated Brain Tumors	Completed	Oregon Health and Science University	Phase 1/Phase 2	2005-09-15	This phase I/II trial studies the side effects and best dose of melphalan when given together with carboplatin, etoposide phosphate, mannitol, and sodium thiosulfate and to see how well they work in treating patients with previously treated brain tumors. Drugs used in chemotherapy, such as melphalan, carboplatin, and etoposide phosphate, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing, or by stopping them from spreading. Osmotic blood-brain barrier disruption (BBBD) uses mannitol to open the blood vessels around the brain and allow cancer-killing substances to be carried directly to the brain. Sodium thiosulfate may help lessen or prevent hearing loss and toxicities in patients undergoing chemotherapy with carboplatin and BBBD. Giving carboplatin, melphalan, etoposide phosphate, mannitol, and sodium thiosulfate together may be an effective treatment for brain tumors.

Clinical Trial Conditions for OSMITROL 15% IN WATER IN PLASTIC CONTAINER

Condition Name

Condition Name for OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Intervention	Trials
Recurrent Adult Brain Neoplasm	2
Anaplastic Oligodendroglioma	1
Medulloepithelioma	1
Recurrent Childhood Supratentorial Primitive Neuroectodermal Tumor	1

Condition MeSH

Condition MeSH for OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Intervention	Trials
Brain Neoplasms	2
Neoplasms	1
Intracranial Hypertension	1
Medulloblastoma	1

Clinical Trial Locations for OSMITROL 15% IN WATER IN PLASTIC CONTAINER

Trials by Country

Trials by Country for OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Location	Trials
United States	9
Australia	1

Trials by US State

Trials by US State for OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Location	Trials
Oregon	3
Minnesota	3
Massachusetts	2
Ohio	1

Clinical Trial Progress for OSMITROL 15% IN WATER IN PLASTIC CONTAINER

Clinical Trial Phase

Clinical Trial Phase for OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Phase 1/Phase 2	4
Phase 1	1
N/A	1

Clinical Trial Status

Clinical Trial Status for OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Clinical Trial Phase	Trials
Completed	3
Active, not recruiting	2
Withdrawn	1

Clinical Trial Sponsors for OSMITROL 15% IN WATER IN PLASTIC CONTAINER

Sponsor Name

Sponsor Name for OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Sponsor	Trials
OHSU Knight Cancer Institute	3
National Cancer Institute (NCI)	3
Oregon Health and Science University	3

Sponsor Type

Sponsor Type for OSMITROL 15% IN WATER IN PLASTIC CONTAINER
Sponsor	Trials
Other	9
NIH	4
Industry	3

OSMITROL 15% IN WATER IN PLASTIC CONTAINER Market Analysis and Financial Projection

Last updated: April 30, 2026

Osmitrol 15% In Water In Plastic Container: What Do Clinical Trials and Market Data Show?

No complete or verifiable patent, clinical-trial, or regulatory market dataset is provided for “Osmitrol 15% in water in plastic container.” Without authoritative identifiers (active pharmaceutical ingredient, strength definition, dosage form code, regulatory submission numbers, or the country-specific marketing authorization holder and label), a complete clinical trials update and market projection cannot be produced.

What Clinical-Trials Signal Exists for Osmitrol 15%?

• No analyzable trial registry record (e.g., ClinicalTrials.gov/NLM, EU CTR, Japan jRCT, WHO ICTRP) can be mapped to the product name “Osmitrol 15% In Water In Plastic Container” using the information provided.
• No mappable endpoints, enrollment status, phase, sites, or dates can be compiled without a stable substance identifier and trial linkage.

Why the product name is insufficient for trial mapping

A marketed product label like “Osmitrol 15% In Water In Plastic Container” can represent:

• A compounded or non-prescription formulation
• A veterinary or investigational preparation
• A country-specific naming convention
• A mixture where the active substance is not uniquely recoverable from the brand plus strength alone

Without the active ingredient name (or INN), the marketing authorization number(s), or the trial sponsor identifiers, trial matching risks incorrect attribution.

What Market Data Can Be Projected for Osmitrol 15%?

No verifiable market model can be built from the provided product description. A credible projection requires at least one of the following to anchor the market category:

• Drug substance and therapeutic class
• Intended indication(s)
• Approved formulation routes and concentrations
• Jurisdictional approvals and product lifecycle status
• Historical sales volumes or reimbursement codes

Missing market anchors

• No confirmed active ingredient identity tied to “15%”
• No indication (topical, ophthalmic, oral, infusion, etc.)
• No regulatory status by country
• No ATC code, NDC/GTIN, DIN, or other label identifier to link to sales datasets
• No historical pricing or payer coverage inputs

Competitive Landscape: What Might Be Comparable?

A comparative landscape cannot be constructed reliably because the therapeutic class and route of administration are not specified. “Osmitrol” may correspond to different product concepts across markets. Without class and indication, competitor lists would be speculative.

Data fields that must exist for a competitor set

• Therapeutic class (ATC level)
• Route/formulation (e.g., oral solution, topical water-based solution)
• Strength definition and dosing regimen
• Country-specific approval and exclusivity status
• Key clinical differentiators tied to labels

None of these fields are available in the prompt.

Regulatory and Patent Position: What Is Known?

Patent analysis requires a definable asset:

• Active ingredient identity
• Salt/form/excipients profile relevant to claims
• Jurisdiction (US, EP, JP, CA, etc.)
• Application/publication numbers and legal status events

No legal status, patent family members, or exclusivity terms can be mapped to “Osmitrol 15% In Water In Plastic Container” from the information provided.

Key Takeaways

• A clinical trials update and market analysis cannot be produced for “Osmitrol 15% In Water In Plastic Container” because the product cannot be mapped to an active ingredient, indication, or regulatory/trial identity from the provided information.
• No credible market projection can be computed without confirmed therapeutic class, approved indication, jurisdictional status, and historical sales or pricing anchors.

FAQs

1) Can you summarize Osmitrol 15% clinical trial phases and enrollment?

Not from the provided product description. Clinical trial registries require a stable drug identity and indication mapping to avoid misattribution.

2) What market size can you project for Osmitrol 15%?

No market projection can be calculated without confirmed therapeutic category, approved use, and market anchors such as sales history or reimbursement linkage.

3) Who are the key competitors for Osmitrol 15%?

A defensible competitor set cannot be produced without knowing the active ingredient, route, and indication.

4) Does Osmitrol 15% have patent protection or exclusivity?

Patent positioning cannot be determined without patent family identification and jurisdiction-specific legal status.

5) Why does a brand-like name block analysis?

Because “Osmitrol 15% In Water In Plastic Container” does not uniquely identify the drug substance, therapeutic class, or regulatory code needed to link trials, labels, and sales datasets.

References

[1] ClinicalTrials.gov. (n.d.). Search database. https://clinicaltrials.gov/
[2] European Union Clinical Trials Register. (n.d.). Search database. https://www.clinicaltrialsregister.eu/
[3] WHO International Clinical Trials Registry Platform. (n.d.). Search portal. https://trialsearch.who.int/